Suppr超能文献

一种用于原发性高级别骨肉瘤手术分期的新系统:伯明翰分类法。

A Novel System for the Surgical Staging of Primary High-grade Osteosarcoma: The Birmingham Classification.

作者信息

Jeys Lee M, Thorne Chris J, Parry Michael, Gaston Czar Louie L, Sumathi Vaiyapuri P, Grimer J Robert

机构信息

School of Life and Health Sciences, Aston University, Birmingham, UK.

The Royal Orthopaedic Hospital NHS Foundation Trust, Bristol Road South, Birmingham, B31 2AP, UK.

出版信息

Clin Orthop Relat Res. 2017 Mar;475(3):842-850. doi: 10.1007/s11999-016-4851-y.

Abstract

BACKGROUND

Chemotherapy response and surgical margins have been shown to be associated with the risk of local recurrence in patients with osteosarcoma. However, existing surgical staging systems fail to reflect the response to chemotherapy or define an appropriate safe metric distance from the tumor that will allow complete excision and closely predict the chance of disease recurrence. We therefore sought to review a group of patients with primary high-grade osteosarcoma treated with neoadjuvant chemotherapy and surgical resection and analyzed margins and chemotherapy response in terms of local recurrence.

QUESTIONS/PURPOSES: (1) What predictor or combination of predictors available to the clinician can be assessed that more reliably predict the likelihood of local recurrence? (2) Can we determine a better predictor of local recurrence-free survival than the currently applied system of surgical margins? (3) Can we determine a better predictor of overall survival than the currently applied system of surgical margins?

METHODS

This retrospective study included all patients with high-grade conventional osteosarcomas without metastasis at diagnosis treated at one center between 1997 and 2012 with preoperative chemotherapy followed by resection or amputation of the primary tumor who were younger than age 50 years with minimum 24-month followup for those still alive. A total of 389 participants matched the inclusion criteria. Univariate log-rank test and multivariate Cox analyses were undertaken to identify predictors of local recurrence-free survival (LRFS). The Birmingham classification was devised on the basis of two stems: the response to chemotherapy (good response = ≥ 90% necrosis; poor response = < 90% necrosis) and margins (< 2 mm or ≥ 2 mm). The 5-year overall survival rate was 67% (95% confidence interval [CI], 61%-71%) and 47 patients developed local recurrence (12%).

RESULTS

Intralesional margins (hazard ratio [HR], 9.9; 95% CI, 1.2-82; p = 0.03 versus radical margin HR, 1) and a poor response to neoadjuvant chemotherapy (HR, 3.8; 95% CI, 1.7-8.4; p = 0.001 versus good response HR, 1) were independent risk factors for local recurrence (LR). The best predictor of LR, however, was a combination of margins ≤ 2 mm and a less than 90% necrosis response to chemotherapy (Birmingham 2b HR, 19.6; 95% CI, 2.6-144; p = 0.003 versus Birmingham 1a; margin >2 mm and more than 90% necrosis HR, 1). Two-stage Cox regression model and higher Harrell's C statistic demonstrate that the Birmingham classification was superior to the Musculoskeletal Tumor Society (MSTS) margin classification for predicting LR (Harrell's C statistic Birmingham classification 0.68, MSTS criteria 0.59). A difference in overall survival was seen between groups of the Birmingham classification (log-rank test p < 0.0001), whereas the MSTS margin system was not discriminatory (log-rank test p = 0.14).

CONCLUSIONS

Based on these observations, we believe that a combination of the recording of surgical margins in millimeters and the response to neoadjuvant chemotherapy can more accurately predict the risk of local recurrence than the current MSTS system. A multicenter collaboration study initiated by the International Society of Limb Salvage is recommended to test the validity of the proposed classification and if these findings are confirmed, this classification system might be considered the standard practice in oncology centers treating patients with osteosarcomas and allow more effective communication of margin status for research.

LEVEL OF EVIDENCE

Level IV, prognostic study.

摘要

背景

化疗反应和手术切缘已被证明与骨肉瘤患者的局部复发风险相关。然而,现有的手术分期系统未能反映对化疗的反应,也未定义一个合适的距肿瘤安全测量距离,以实现完整切除并准确预测疾病复发的可能性。因此,我们试图回顾一组接受新辅助化疗和手术切除治疗的原发性高级别骨肉瘤患者,并从局部复发方面分析切缘和化疗反应。

问题/目的:(1)临床医生可用的哪些预测指标或预测指标组合能更可靠地预测局部复发的可能性?(2)我们能否确定一个比目前应用的手术切缘系统更好的无局部复发生存预测指标?(3)我们能否确定一个比目前应用的手术切缘系统更好的总生存预测指标?

方法

这项回顾性研究纳入了所有于1997年至2012年在一个中心接受治疗的诊断时无转移的高级别传统骨肉瘤患者,这些患者接受了术前化疗,随后对原发肿瘤进行切除或截肢,年龄小于50岁,对仍存活的患者进行至少24个月的随访。共有389名参与者符合纳入标准。采用单因素对数秩检验和多因素Cox分析来确定无局部复发生存(LRFS)的预测指标。伯明翰分类法基于两个主干制定:化疗反应(良好反应=坏死≥90%;不良反应=坏死<90%)和切缘(<2mm或≥2mm)。5年总生存率为67%(95%置信区间[CI],61%-71%),47例患者发生局部复发(12%)。

结果

瘤内切缘(风险比[HR],9.9;95%CI,1.2-82;p=0.03,与根治性切缘HR=1相比)和对新辅助化疗反应不良(HR,3.8;95%CI,1.7-8.4;p=0.001,与良好反应HR=1相比)是局部复发(LR) 的独立危险因素。然而,LR的最佳预测指标是切缘≤2mm且对化疗坏死反应小于90%的组合(伯明翰2b HR,19.6;95%CI,2.6-144;p=0.003,与伯明翰1a相比;切缘>2mm且坏死超过90% HR=1)。两阶段Cox回归模型和更高的Harrell's C统计量表明,伯明翰分类法在预测LR方面优于肌肉骨骼肿瘤学会(MSTS)切缘分类法(Harrell's C统计量伯明翰分类法为0.68,MSTS标准为0.59)。伯明翰分类组之间总生存率存在差异(对数秩检验p<0.0001),而MSTS切缘系统无鉴别力(对数秩检验p=0.14)。

结论

基于这些观察结果,我们认为以毫米记录手术切缘并结合新辅助化疗反应,比目前的MSTS系统能更准确地预测局部复发风险。建议由国际肢体保全学会发起一项多中心合作研究,以检验所提议分类法的有效性。如果这些发现得到证实,该分类系统可能会被视为肿瘤中心治疗骨肉瘤患者的标准做法,并有助于更有效地交流切缘状态以供研究使用。

证据水平

IV级,预后研究。

相似文献

1
A Novel System for the Surgical Staging of Primary High-grade Osteosarcoma: The Birmingham Classification.
Clin Orthop Relat Res. 2017 Mar;475(3):842-850. doi: 10.1007/s11999-016-4851-y.
7
Do Surgical Margins Affect Local Recurrence and Survival in Extremity, Nonmetastatic, High-grade Osteosarcoma?
Clin Orthop Relat Res. 2016 Mar;474(3):677-83. doi: 10.1007/s11999-015-4359-x.
8
Should High-grade Extraosseous Osteosarcoma Be Treated With Multimodality Therapy Like Other Soft Tissue Sarcomas?
Clin Orthop Relat Res. 2015 Nov;473(11):3604-11. doi: 10.1007/s11999-015-4463-y. Epub 2015 Jul 22.
9
What are the factors that affect survival and relapse after local recurrence of osteosarcoma?
Clin Orthop Relat Res. 2014 Oct;472(10):3188-95. doi: 10.1007/s11999-014-3759-7. Epub 2014 Jul 1.
10
Survival, recurrence, and function after epiphyseal preservation and allograft reconstruction in osteosarcoma of the knee.
Clin Orthop Relat Res. 2015 May;473(5):1789-96. doi: 10.1007/s11999-014-4028-5. Epub 2014 Oct 29.

引用本文的文献

2
Integrating Radiogenomics and Machine Learning in Musculoskeletal Oncology Care.
Diagnostics (Basel). 2025 May 29;15(11):1377. doi: 10.3390/diagnostics15111377.
3
UK guidelines for the management of bone sarcomas.
Br J Cancer. 2025 Jan;132(1):32-48. doi: 10.1038/s41416-024-02868-4. Epub 2024 Nov 16.
5
Accuracy of bony resection under computer-assisted navigation for bone sarcomas around the knee.
World J Surg Oncol. 2023 Jun 21;21(1):187. doi: 10.1186/s12957-023-03071-0.
7
[Primary malignant bone tumors].
Orthopadie (Heidelb). 2023 Jun;52(6):509-522. doi: 10.1007/s00132-023-04387-1. Epub 2023 Jun 6.
8
Malignant Bone and Soft Tissue Lesions of the Foot.
J Clin Med. 2023 Apr 21;12(8):3038. doi: 10.3390/jcm12083038.
10
Analysis of prognostic factors and histopathological response to neoadjuvant chemotherapy in osteosarcoma.
Jt Dis Relat Surg. 2023;34(1):196-206. doi: 10.52312/jdrs.2023.902. Epub 2023 Jan 14.

本文引用的文献

2
Do Surgical Margins Affect Local Recurrence and Survival in Extremity, Nonmetastatic, High-grade Osteosarcoma?
Clin Orthop Relat Res. 2016 Mar;474(3):677-83. doi: 10.1007/s11999-015-4359-x.
4
EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment.
Ann Oncol. 2015 Feb;26(2):407-14. doi: 10.1093/annonc/mdu526. Epub 2014 Nov 24.
6
Reliability of Margin Assessment after Surgery for Extremity Soft Tissue Sarcoma: The SSG Experience.
Sarcoma. 2012;2012:290698. doi: 10.1155/2012/290698. Epub 2012 Jun 18.
9
18F-FDG PET response to neoadjuvant chemotherapy for Ewing sarcoma and osteosarcoma are different.
Skeletal Radiol. 2011 Aug;40(8):1007-15. doi: 10.1007/s00256-011-1096-4. Epub 2011 Feb 6.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验